Journal ArticleOPEN ACCESS

A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer

  • Planchard D
  • Li B
  • Murakami H
  • et al.
Annals of Oncology (2019) 30 ii66-ii67
DOI: 10.1093/annonc/mdz063.081
N/ACitations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

… every 3 weeks) in HER2-overexpressing or -mutated unresectable and/or metastatic nonsquamous NSCLC … di Saronno, Saronno, Italy Background: Squamous non-small cell lung cancer (Sq-NSCLC … In the last decades, first- line chemotherapy (Ctx) for advanced Sq-NSCLC has …

Cite

CITATION STYLE

APA

Planchard, D., Li, B. T., Murakami, H., Shiga, R., Lee, C. C., Wang, K., & Jänne, P. A. (2019). A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer. Annals of Oncology, 30, ii66–ii67. https://doi.org/10.1093/annonc/mdz063.081

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free